1. Dejka Araujo, MD MD Anderson Cancer Center, Houston, TX
A PHASE II TRIAL OF PERIFOSINE IN PATIENTS WITH CHEMO-INSENSITIVE SARCOMAS A SARCOMA ALLIANCE FOR RESEARCH THROUGH COLLABORATION (SARC) STUDY Study Update – November 2007
Dejka Araujo, MD
MD Anderson Cancer Center, Houston, TX

2. Patients with < 2 forms of prior chemotherapy stratified by
Extra-Skeletal Myxoid
Chondrosarcoma
Conventional
Chondrosarcoma
Alveolar Soft Part
Sarcoma
Perifosine 100 mg po qhs daily
Evaluate q 12 weeks
SD, PR or CR
Progression
Continue On Study
Remove From Study

3. Objectives Primary Secondary
Evaluate the response rate defined by both Choi and RECIST criteria of single agent perifosine
Secondary
Evaluate Time to Progression
Evaluate the Clinical Benefit Rate (SD of 6 mo’s or greater)

4. Major Inclusion / Exclusion
Measurable Disease
Documented progression by Choi Criteria
Age > 13 years
Exclusion
> 2 prior cytotoxic regimens for metastatic disease (unless exempted)

5. Participants (12) / Enrollment (59)
Extra-Skeletal Myxoid
Chondrosarcoma - 15
Conventional
Chondrosarcoma - 33
Alveolar Soft Part
Sarcoma - 11
MD Anderson – 13
Dejka Araujo, MD
Penn – 12
Arthur Staddon, MD
Sarcoma Oncology – 11
Sant Chawla, MD
MSKCC - 8
Robert Maki, MD
Michigan - 5
Scott Schuetze, MD
Mass General – 5
Edwin Choy, MD
Fox Chase – 2
Margaret von Mehren, MD
Washington Cancer – 2
Dennis Priebat, MD
OHSU – 1
Christopher Ryan, MD
Others Open:
DFCI, Moffitt, UFL